Access our list of medicines
ELIQUIS (apixaban) is indicated for prevention of stroke / systemic embolism in adult patients with NVAF, treatment of DVT and PE, and prevention of recurrent DVT and PE in adults.
Dacomitinib is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations.
1. Granger CB, et al. N Engl J Med. 2011;365:981-992
PP-ELI-IND-0586 created on 24th Sep 2020